일양약품

007570KOSPI의약품 제조업

47.8 / 100

Reference Date: 2026-06-10

Financial Score13.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 22.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ilwang Pharm focuses on developing innovative drugs like 'Noltek' (ulcer treatment) and 'Sufekt' (leukemia treatment), expanding into global markets, and strengthening long-term growth through R&D investments. In 2022, the company reported consolidated sales of 2.724 trillion KRW and operating profit of 49 billion KRW, with ongoing market expansion in China and Mexico.

Number of Employees

665people

Average Salary

84.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

21.52Industry Average 11.931.5Point

1.8x industry avg (risky)

PBR

0.64Industry Average 0.895.5Point

Lower than industry avg (good)

ROE

2.97Industry Average 4.012.5Point

Below industry avg

Debt Ratio

18.54Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼43.9% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.2% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
일양약품 항궤양제 ‘놀텍’, 18년차에도 성장세 지속...왜?
일양약품의 항궤양제 놀텍이 장기적인 성장을 이어가며 시장에서의 지속적인 성공을 보여주고 있다.
Positive
일양약품, 증국 길림에 176억원 투자…'원비디' 현지 생산 노린다
일양약품의 중국 투자로 '원비디' 생산 기반 확보, 중국 시장 진출 확대 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 8,070Won52-week high 15,13052-week low 8,070

1-month return0.0Point

1m -22.10% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-28
Neutral분기보고서 (2026.03)2026-05-15
Neutral타법인주식및출자증권취득결정2026-05-14